Update of pathogen reduction technology for therapeutic plasma

Area of Science:

• Transfusion Medicine
• Infectious Disease Surveillance
• Molecular Diagnostics

Background:

• Blood products undergo pathogen screening, yet residual transmission risks persist.
• The
• window period
• between infection and detectable antibodies poses a challenge.
• Emerging infectious agents, like West Nile Virus (WNV), present ongoing threats to blood supply safety.

Purpose of the Study:

• To provide an update on advancements in blood component safety.
• To highlight the role of nucleic acid-based testing in mitigating transfusion-transmitted infections.
• To discuss the limitations of current screening methods against novel pathogens.

Main Methods:

• Review of nucleic acid amplification testing (NAT) for viral pathogens (e.g., HIV, HCV).
• Discussion of enhanced laboratory screening sensitivity and donor selection criteria.
• Analysis of emerging infectious agents and their impact on blood safety.

Main Results:

• Nucleic acid amplification testing (NAT) has significantly reduced the window period for key viruses.
• Improved screening methods and donor criteria have decreased the incidence of many transfusion-transmitted pathogens.
• Transfusion-related risks, while reduced, are not entirely eliminated, necessitating continuous improvement.

Conclusions:

• Ongoing advancements in molecular diagnostics are critical for enhancing blood product safety.
• The blood supply remains vulnerable to new and emerging infectious agents.
• A multi-faceted approach, including advanced testing and vigilant surveillance, is essential to protect recipients.